CRL
Charles River Laboratories International, Inc.
CRL's fundamentals are mixed, but it looks expensive: trading at 355x earnings, about 12 times its usual 29x.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CRL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Weak |
CRL's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CRL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $21.43 | -94% |
| Fair | 29x | $27.64 | -92% |
| Expensive | 46x | $44.08 | -87% |
| Current | 355x | $341 | — |
Historical ranges are pointers, not guarantees.
CRL's PE is in its expensive range at 355x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CRL Forward outlook
There aren't enough analyst estimates for CRL to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CRL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.96 | +$2.47 |
| Q2 2026 | -$4.80 | -$3.52 |
| Q1 2026 | -$3.71 | -$3.11 |
| Q4 2025 | -$2.91 | -1555% |
| Q3 2025 | -$1.51 | -119% |
| Q2 2025 | -$1.28 | -115% |
| Q1 2025 | -$0.60 | -107% |
| Q4 2024 | $0.20 | -98% |
CRL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CRL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $982.7M | -2.2% |
| Q2 2026 | $1B | -2.7% |
| Q1 2026 | $995.8M | +1.2% |
| Q4 2025 | $994.2M | -0.8% |
| Q3 2025 | $1B | -0.5% |
| Q2 2025 | $1B | +0.6% |
| Q1 2025 | $984.2M | -2.7% |
| Q4 2024 | $1B | -1.1% |
CRL's revenue grew through 2022 and has held roughly level since: $983M last quarter, down 2.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +7.3 points |
| Q2 2026 | 12% | +2.2 points |
| Q1 2026 | 12% | +4.4 points |
| Q4 2025 | -29% | -12 points |
| Q3 2025 | 13% | +1.7 points |
| Q2 2025 | 9.7% | -5.1 points |
| Q1 2025 | 7.6% | -4.9 points |
| Q4 2024 | -17% | -30 points |
CRL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CRL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CRL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $207.3M | +16% |
| Q2 2026 | $148.6M | -12% |
| Q1 2026 | -$14.8M | -113% |
| Q4 2025 | $58.6M | -30% |
| Q3 2025 | $178.2M | -16% |
| Q2 2025 | $169.3M | +9.9% |
| Q1 2025 | $112.4M | +121% |
| Q4 2024 | $83.7M | -41% |
CRL still generates free cash flow, though less than at its 2024 peak: $400M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CRL on cash flow, with more consistent year-over-year improvement.
CRL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +563K shares |
| 1 year | -1.7% | -842K shares |
| 3 years | -5.9% | -3M shares |
| 5 years | -5.8% | -3M shares |
| Available history | -2.2% | -1.1M shares |
CRL has 49M diluted shares, down 1.7% from a year ago, with $324M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $224,000 |
| Q2 2026 | $115.6M |
| Q1 2026 | $208.3M |
| Q4 2025 | $96,000 |
| Q3 2025 | $93,000 |
| Q2 2025 | $7.4M |
| Q1 2025 | $353.1M |
| Q4 2024 | $124,000 |
CRL spent $324M buying back its own shares over the past year, down 10% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CRL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CRL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.1x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 5.9x | High |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.9x | Elevated |
| Q1 2025 | 4.0x | Elevated |
| Q4 2024 | 3.5x | Elevated |
CRL's net debt is about 5.1 years of its operating earnings (EBITDA), up from 3.5 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CRL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.9 | Overbought |
| Stochastic | 75.1 | Neutral |
CRL's weekly RSI is 72 (overbought) and its Stochastic is 75 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CRL PE vs Healthcare Sector
| Metric | CRL | Sector median | Relative |
|---|---|---|---|
| PE | 355x | 26x | 1,273% above |
| PE % | 96 | 29 | 67 pts above |
CRL is trading at 355x earnings, a 1273% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CRL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $321.0 | 6.2% above |
| 20 week MA | $284.7 | 20% above |
| 50 week MA | $223.9 | 52% above |
| 100 week MA | $191.1 | 78% above |
| 200 week MA | $201.5 | 69% above |
CRL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CRL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $151.9 | $251.7 | +66% |
| 2021 | $251.7 | $369.2 | +47% |
| 2022 | $369.2 | $218.5 | -41% |
| 2023 | $218.5 | $236.4 | +8.2% |
| 2024 | $236.4 | $186.2 | -21% |
| 2025 | $186.2 | $203.7 | +9.4% |
| 2026 YTD | $203.7 | $340.8 | +67% |
CRL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.